Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Davies, A, Cummin, TE, Barrans, S et al. (21 more authors) (2019) Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. The Lancet Oncology, 20 (5). pp. 649-662. ISSN 1470-2045

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Dates:
  • Published: May 2019
  • Accepted: 7 December 2018
  • Published (online): 1 April 2019
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Biological Sciences (Leeds) > School of Molecular and Cellular Biology (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Experimental Haematology (Leeds)
Funding Information:
FunderGrant number
Cancer Research UKC7845/A17723
Depositing User: Symplectic Publications
Date Deposited: 01 May 2019 13:13
Last Modified: 07 May 2019 14:07
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/s1470-2045(18)30935-5

Share / Export

Statistics